We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.00 | 0.21% | 1,405.00 | 1,406.00 | 1,406.50 | 1,410.50 | 1,399.50 | 1,404.00 | 13,745,946 | 16:35:16 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.83 | 58.11B |
From Feb 2020 to Feb 2025
By Josh Beckerman
CureVac NV shares fell 52% to $45.45 in after-hours trading as the company reported unfavorable interim data from a Covid-19 vaccine clinical trial.
"In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria," CureVac said.
The HERALD study, conducted by CureVac in conjunction with Bayer, enrolled about 40,000 people in 10 countries in Latin America and Europe.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 16, 2021 17:40 ET (21:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
